<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859504</url>
  </required_header>
  <id_info>
    <org_study_id>20191836</org_study_id>
    <nct_id>NCT04859504</nct_id>
  </id_info>
  <brief_title>Developing Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia</brief_title>
  <official_title>Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia Patients: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Negative symptoms are core symptoms in schizophrenia which play an important role in clinical&#xD;
      outcomes and impede patients to return to society. Anti-psychotic medicines have shown&#xD;
      limited effect in improving negative symptoms and cognitive functioning, whereas non-invasive&#xD;
      neuromodulations, i.e. , transcranial alternating current stimulation (tACS), have shown&#xD;
      promising potentials. Recently new evidence of brain structural and functional alterations&#xD;
      has been provided by neuroimaging studies. Brady RO et al. found cerebellar-prefrontal&#xD;
      network connectivity was related to negative symptoms in schizophrenia. It provides clues for&#xD;
      developing a new tACS protocol targeting improving negative symptoms, in which dual-channel&#xD;
      high-density alternating current stimulations were delivered over both the right dorsolateral&#xD;
      prefrontal cortex and cerebellum simultaneously.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reductive ratio of PANSS-negative symptoms scores</measure>
    <time_frame>At 1 week and 3 weeks</time_frame>
    <description>differences of reductive ratio of PANSS-negative symptoms scores after between active and sham tACS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of PANSS total scores</measure>
    <time_frame>At 1 week and 3 weeks</time_frame>
    <description>changes of PANSS total scores before and after active or sham tACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive functioning changes using MCCB</measure>
    <time_frame>At 1 week</time_frame>
    <description>changes of MCCB scores before and after active or sham tACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of P300 activity</measure>
    <time_frame>At 1 week</time_frame>
    <description>changes of P300 activity at baseline and after 10-session tACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of MMN activity</measure>
    <time_frame>At 1 week</time_frame>
    <description>changes of MMN activity at baseline and after 10-session tACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of power of resting-state EEG activity</measure>
    <time_frame>At 1 day and 1 week</time_frame>
    <description>changes of power of resting-state EEG activity at baseline, after 1-session tACS and after 10-session tACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>centroid value from fNIRS recording before and after active or sham tACS</measure>
    <time_frame>At 1 week</time_frame>
    <description>centroid value from fNIRS recording before and after active or sham tACS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Integral value from fNIRS recording before and after active or sham tACS</measure>
    <time_frame>At 1 week</time_frame>
    <description>Intergral value from fNIRS recording before and after active or sham tACS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Transcranial Alternating Current Stimulations</condition>
  <condition>Negative Symptoms</condition>
  <arm_group>
    <arm_group_label>Active tACS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active tACS will be applied twice daily for 5 days. In each session, dual-channel high-density theta(7Hz) tACS stimulations will be delivered over the right DLPFC (one anodal electrode at F4, between -1.2mA and 1.2 mA; two cathodal electrodes at AF4 and FC6, between -0.6mA and 0.6mA) and cerebellum (one anodal electrode at Oz, between -1 mA and 1mA; two cathodal electrodes at PO3 and PO4, between -0.5mA and 0.5mA) lasting 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tACS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tACS will be also applied twice daily for 5 days.The parameters of tACS electrodes numbers, locations, and current duration are all the same with active tACS. But sham tACS begin with a fade in over 3s to the peak, followed immediately by no current stimulation for 20 minutes and a fade out of 3s.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial alternating current stimulation (NE Starstim)</intervention_name>
    <description>dual-channel theta-tACS over right DLPFC and cerebellum simultaneously</description>
    <arm_group_label>Active tACS</arm_group_label>
    <arm_group_label>Sham tACS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  meet the DSM-V diagnostic criteria for schizophrenia;&#xD;
&#xD;
          -  present with prominent negative symptoms with PANSS-negative scores &gt;20, at least one&#xD;
             score of PANSS N1-N7 &gt;3, and reductive ratio of PANSS-negative in the past two weeks&#xD;
             before recruitment &lt;10%;&#xD;
&#xD;
          -  stable usage and dosage of anti-psychotic medicines in the past two weeks and during&#xD;
             the tACS intervention.&#xD;
&#xD;
          -  age within 18-60;&#xD;
&#xD;
          -  illness duration &gt;1year;&#xD;
&#xD;
          -  education at least 6 years;&#xD;
&#xD;
          -  written consent of receiving tACS intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Meet any DSM-V diagnostic criteria of any other psychiatric disorders besides&#xD;
             schizophrenia ;&#xD;
&#xD;
          -  any history of alcohol or substance dependence in the past 3 months;&#xD;
&#xD;
          -  any other major physical disease (i.e., Sensorimotor disorder, neurological disease);&#xD;
&#xD;
          -  any metal implants or any other tACS contraindication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingying Tang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianhua Sheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingying Tang, PhD</last_name>
    <phone>86-21-34773230</phone>
    <email>yytang0522@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianhua Sheng, MD</last_name>
    <phone>86-21-34773459</phone>
    <email>shengjianhua66@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yingying Tang</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingying Tang, PhD</last_name>
      <phone>86-21-34773230</phone>
      <email>yytang0522@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianhua Sheng, MD</last_name>
      <phone>86-21-34773759</phone>
      <email>shengjianhua66@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yingying Tang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianhua Sheng, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Brady RO Jr, Gonsalvez I, Lee I, Öngür D, Seidman LJ, Schmahmann JD, Eack SM, Keshavan MS, Pascual-Leone A, Halko MA. Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia. Am J Psychiatry. 2019 Jul 1;176(7):512-520. doi: 10.1176/appi.ajp.2018.18040429. Epub 2019 Jan 30.</citation>
    <PMID>30696271</PMID>
  </reference>
  <reference>
    <citation>Reinhart RMG, Nguyen JA. Working memory revived in older adults by synchronizing rhythmic brain circuits. Nat Neurosci. 2019 May;22(5):820-827. doi: 10.1038/s41593-019-0371-x. Epub 2019 Apr 8.</citation>
    <PMID>30962628</PMID>
  </reference>
  <reference>
    <citation>Smith RC, Md WL, Wang Y, Jiang J, Wang J, Szabo V, Faull R, Jin H, Davis JM, Li C. Effects of transcranial direct current stimulation on cognition and symptoms in Chinese patients with schizophrenia(✰). Psychiatry Res. 2020 Feb;284:112617. doi: 10.1016/j.psychres.2019.112617. Epub 2019 Nov 2.</citation>
    <PMID>31806403</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We will decide IPD or not when the clinical trial is completed.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

